Agilon Health, Inc. Form 8-K Summary
Business context and reporting period
Agilon Health filed this Current Report on Form 8-K on January 9, 2023 under Item 7.01, Regulation FD Disclosure. Management provided updates in connection with the 41st Annual J.P. Morgan Healthcare Conference. The filing does not contain a quarterly or annual financial statement; the guidance discussed relates to fiscal years 2022 and 2023.
Key financial and operating metrics
- 2022 Adjusted EBITDA guidance: Reaffirmed at $2 million to $7 million for the full year.
- 2023 Adjusted EBITDA guidance: Preliminary guidance of $75 million to $90 million.
- Medicare Advantage membership: Preliminary outlook of more than 400,000 members at year-end 2023.
- Prior membership outlook: Approximately 390,000 members at year-end 2023.
- Revenue, net income, cash flow, margins, debt, and liquidity: The filing text does not provide clear current-period values or guidance for these measures.
Material changes versus the prior comparable outlook
The company increased its preliminary year-end 2023 Medicare Advantage membership outlook from approximately 390,000 members to more than 400,000 members. It introduced preliminary 2023 Adjusted EBITDA guidance of $75 million to $90 million while reaffirming its 2022 Adjusted EBITDA guidance of $2 million to $7 million.
Guidance, outlook, risks, and unusual items
Adjusted EBITDA is a non-GAAP measure defined by the company as net income or loss adjusted for discontinued operations, interest expense, income taxes, depreciation and amortization, geography entry costs, share-based compensation, severance and related costs, and certain other items excluded from ongoing operating performance. The company did not reconcile the Adjusted EBITDA guidance to net income or loss and did not provide net income or loss guidance because of uncertainty regarding items affecting that measure.
Management cautioned that the outlook is forward-looking and subject to risks, including continued net losses and rising expenses; medical costs exceeding medical revenue; difficulty developing new geographies, physician relationships, and payor contracts; membership reductions; challenges transitioning physician partners to a Total Care Model; inaccurate market, revenue, or medical-cost assumptions; reliance on government healthcare programs, payors, physician partners, and CMS methodologies; reimbursement or regulatory changes; data security incidents; subsidiary funding needs; and potential future indebtedness.
The filing also notes that Adjusted EBITDA may not be comparable with similarly titled measures reported by other companies.
Important facts for investors to verify
- Verify full-year 2022 actual Adjusted EBITDA against the reaffirmed $2 million to $7 million range.
- Verify the reconciliation of 2023 Adjusted EBITDA to GAAP net income or loss when available.
- Track whether year-end 2023 Medicare Advantage membership exceeds 400,000.
- Review subsequent filings for revenue, medical expense trends, cash flow, liquidity, debt, and profitability.
- Assess the effect of payor contracts, CMS reimbursement methodologies, regulatory changes, and physician-partner execution on the outlook.